Valuation: Cell Source, Inc.

Market Cap 2.44Cr 2.12Cr 1.98Cr 1.81Cr 3.42Cr 233.02Cr 3.48Cr 23Cr 9.14Cr 116.01Cr 9.17Cr 8.97Cr 389Cr P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 3.49Cr 3.04Cr 2.83Cr 2.59Cr 4.9Cr 333.34Cr 4.97Cr 33Cr 13Cr 165.95Cr 13Cr 13Cr 556.45Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day+4.71%
1 week+36.92%
1 month+14.43%
3 months+8.86%
Current year+78.00%
1 week 0.57
Extreme 0.571
0.89
1 month 0.53
Extreme 0.531
0.95
Current year 0.41
Extreme 0.4134
2.25
1 year 0.3
Extreme 0.3022
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 30/06/2014
Director TitleAgeSince
Chairman 77 18/05/2015
Director/Board Member 82 25/03/2021
Director/Board Member 72 10/03/2022
Date Insider Type Main position Quantity % Market Cap.
09/08/21 Others

Director

8,00,000 2.4492%
30/06/21 Others

Director

4,860 0.0149%
30/06/21 Others

Chairman

2,976 0.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+4.71%+36.92%+134.21%+42,280.95% 6.05Cr
+2.35%+2.74%+33.41%+79.20% 5.65TCr
-0.21%-7.38%+25.34%+63.02% 5.36TCr
-2.44%+1.40%-15.74%-16.80% 2.29TCr
-2.85%-7.78%-8.09%+346.36% 2.14TCr
+2.49%-0.92%+20.31%-12.15% 2.03TCr
+0.79%-1.06%+29.29%-33.32% 1.76TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
-5.25%-4.23%+46.41%+169.05% 1.33TCr
+3.41%-6.61%+163.08%+280.43% 1.35TCr
Average +0.36%+0.28%+44.45%+4,369.71% 2.34TCr
Weighted average by Cap. +0.23%-2.95%+28.70%+130.88%

Financials

2023 2024
Net sales - -
Net income -53.21L -46.26L -43.06L -39.53L -74.65L -51Cr -75.81L -5.08Cr -1.99Cr -25Cr -2Cr -1.95Cr -85Cr -45.13L -39.23L -36.51L -33.52L -63.31L -43Cr -64.29L -4.3Cr -1.69Cr -21Cr -1.69Cr -1.66Cr -72Cr
Net Debt 92.74L 80.62L 75.04L 68.89L 1.3Cr 89Cr 1.32Cr 8.85Cr 3.47Cr 44Cr 3.48Cr 3.41Cr 147.79Cr 1.05Cr 91.35L 85.02L 78.06L 1.47Cr 100.31Cr 1.5Cr 10Cr 3.93Cr 50Cr 3.95Cr 3.86Cr 167.46Cr
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
1
Date Price Change Volume
31/26/31 $0.8900 +4.71% 250
29/26/29 $0.8500 +3.24% 1,200
28/26/28 $0.8233 -2.10% 300
27/26/27 $0.8410 +29.38% 200
24/26/24 $0.6500 +0.78% 400
  1. Stock Market
  2. Stocks
  3. CLCS Stock